TAK‐875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β‐cell dysfunction in Zucker diabetic fatty rats
Authors:
Open Access
- 12 July 2013
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 170 (3) , 568-580
Abstract
Background and Purpose: TAK‐875, a selective GPCR40/free fatty acid receptor 1 agonist, improves glycaemic control by increasing glucose‐dependent insulin secretion. Metformin is a first‐line drug for treatment of type 2 diabetes that improves peripheral insulin resistance. Based on complementary mechanism of action, combining these agents is expected to enhance glycaemic control. Here, we evaluated the chronic effects of TAK‐875 monotherapy and combination therapy with metformin in diabetic rats.Experimental Approach: Long‐term effects on glycaemic control and β‐cell function were evaluated using Zucker diabetic fatty (ZDF) rats, which develop diabetes with hyperlipidaemia and progressive β‐cell dysfunction.Key Results: Single doses of TAK‐875 (3–10 mg·kg−1) and metformin (50–150 mg·kg−1) significantly improved both postprandial and fasting hyperglycaemia, and additive improvements were observed in their combination. Six‐week treatment with TAK‐875 (10 mg·kg−1, b.i.d.) significantly decreased glycosylated Hb (GHb) by 1.7%, and the effect was additively enhanced by combination with metformin (50 mg·kg−1, q.d.; GHb: −2.4%). This improvement in glycaemic control in the combination group was accompanied by significant 3.2‐fold increase in fasting plasma insulin levels. Pancreatic insulin content was maintained at a level comparable to that in normal rats by combination treatment (vehicle: 26, combination: 67.1; normal lean: 69.1 ng·mg−1 pancreas) without affecting pancreatic glucagon content. Immunohistochemical analyses revealed normal morphology, enhanced pancreas duodenum homeobox‐1 expression and increased PCNA‐positive cells in islets of the combination group.Conclusion and Implications: Our results indicate that combination therapy with TAK‐875 and metformin could be a valuable strategy for glycaemic control and β‐cell preservation in type 2 diabetes.Keywords
This publication has 54 references indexed in Scilit:
- Chronic activation of a designer Gq-coupled receptor improves β cell functionJournal of Clinical Investigation, 2013
- TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet, 2012
- The Effects of TAK-875, a Selective G Protein-Coupled Receptor 40/Free Fatty Acid 1 Agonist, on Insulin and Glucagon Secretion in Isolated Rat and Human IsletsThe Journal of Pharmacology and Experimental Therapeutics, 2012
- AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in RodentsPLOS ONE, 2011
- TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic RatsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent PathwaysCell Metabolism, 2011
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Combining a dipeptidyl peptidase‐4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β‐cell function in db/db miceBritish Journal of Pharmacology, 2009
- Increased pancreatic islet mass is accompanied by activation of the insulin receptor substrate‐2/serine‐threonine kinase pathway and augmented cyclin D2 protein levels in insulin‐resistant ratsInternational Journal of Experimental Pathology, 2008